Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma

Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma

Abstract Background Immunotherapies that target immune-checkpoint molecules such PD-1 have helped to achieve durable responses in melanoma treatment. However, 25% of melanoma patients who showed objective responses to PD-1 blockade develop resistance and suffer from disease progression and ultimatel...

Full description

Bibliographic Details
Main Authors: Nanumi Han, Muhammad Baghdadi, Kozo Ishikawa, Hiraku Endo, Takuto Kobayashi, Haruka Wada, Keisuke Imafuku, Hiroo Hata, Ken-ichiro Seino
Format: Article
Language:English
Published: BMC 2018-03-01
Series:Inflammation and Regeneration
Subjects:
Interleukin-34
Immunotherapy
Melanoma
Tumor-associated macrophage
Online Access:http://link.springer.com/article/10.1186/s41232-018-0060-2

Internet

http://link.springer.com/article/10.1186/s41232-018-0060-2

Similar Items